Skip to contentB
Bioxytran, Inc
B
BIXTBioxytran, Inc Q1 2015 · 10-Q
Revenue$62.49K$62.49K−70.0% vs Q1 2014 Net Income-$39.06K-$39.06KN/M vs Q1 2014 EPS Diluted-$0.01-$0.01N/M vs Q1 2014 Gross Profit$47,942−68.9% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bioxytran, Inc · CIK 1445815 · Engraved from SEC EDGAR
Operating Cash Flow-$3,438N/M Margins · derivedGross margin76.7%+2.7 pt vs Q1 2014
Operating margin-59.5%−91.1 pt vs Q1 2014
Net margin-62.5%−92.6 pt vs Q1 2014
ended Mar 31, 2015 · filed May 19, 2015 · 49 d after period end